Rodón, Jordi
Demanse, David
Rugo, Hope S.
Burris, Howard A.
Simó, Rafael
Farooki, Azeez
Wellons, Melissa F.
André, Fabrice
Hu, Huilin
Vuina, Dragica
Quadt, Cornelia
Juric, Dejan
Funding for this research was provided by:
Novartis Pharmaceuticals Corporation
Article History
Received: 18 August 2023
Accepted: 18 January 2024
First Online: 4 March 2024
Declarations
:
: All participants in each trial provided written informed consent. All trials were approved by an independent ethics committee and institutional review board at each site and were conducted per the Declaration of Helsinki and Good Clinical Practice.
: All named authors have contributed to the manuscript and agreed to its submission.
: Jordi Rodón reports receiving consulting and travel fees from Novartis, Eli Lilly, Orion Pharmaceuticals, Servier Pharmaceuticals, Peptomyc, Merck Sharp & Dohme, Kelun Pharmaceutical/Klus Pharma, Spectrum Pharmaceuticals Inc, Pfizer, Roche Pharmaceuticals, Ellipses Pharma, NovellusDx, Ionctura and Molecular Partners (including serving on the scientific advisory board from 2015-present), receiving research funding from Blueprint Pharmaceuticals, Bayer and Novartis; David Demanse, Huilin Hu, Dragica Vuina, Cornelia Quadt report employment and stock ownership from Novartis; Hope S. Rugo reports grants from Plexxikon, Macrogenics, OBI Pharma, Eisai, Pfizer, Novartis, Eli Lilly, GlaxoSmithKline, Genentech, Celsion, Merck; fees for travel, accommodations, and expenses from Novartis, Roche/Genentech, OBI Pharma, Bayer, and Pfizer; speaker’s bureau for Genomic Health; Howard A. Burris, Rafael Simó, Melissa F. Wellons have nothing to report; Azeez Farooki reports being a member of a data safety monitoring board for a current Novartis study; Fabrice André reports research funding from AstraZeneca, Lilly, Novartis, Pfizer, Roche; Dejan Juric reports scientific advisory board for Novartis, Genentech, Eisai, Ipsen, EMD Serono.